Monday, July 6, 2009

Coleman Research Group’s Healthcare department highlights AMA open to government-funded health insurance and diprivan not approved for sleep disorders

Coleman Research Group’s Healthcare Team facilitates consultations between our clients (institutional investors) and leading healthcare professionals on a wide variety of topics including pharmaceuticals, biotechnology, clinical research, medical devices, healthcare providers, insurance, and regulatory issues.

Our Healthcare network spans technology industries across the globe and includes doctors, researchers, scientists, healthcare executives, consultants, and former regulatory officials.

********************************

Diprivan not approved for sleep disorders

(CNN) -- Diprivan is a powerful I.V. anesthetic drug used for patients undergoing certain surgeries and diagnostic procedures.

Patients undergoing surgery may receive Diprivan to keep them sedated during the procedure.

The drug is making headlines with the claim from a nurse who worked for pop icon Michael Jackson that the singer, who died June 25, had repeatedly asked her about the drug. Nurse Cherilyn Lee told CNN that Jackson had brought up Diprivan about three months ago, saying he needed it for insomnia and that his doctor said it was safe.

"He said, 'I am so sleepy. I cannot sleep. I want to have at least eight hours of sleep,'" Lee told CNN's Anderson Cooper.

********************************

AMA open to government-funded health insurance option

WASHINGTON (CNN) -- President Obama signed landmark legislation Monday giving the Food and Drug Administration new power to regulate the manufacturing, marketing and sale of tobacco.

President Obama says the new law "represents change that's been decades in the making."

The Family Smoking Prevention and Tobacco Control Act gives the FDA power to ban candy-flavored and fruit-flavored cigarettes, widely considered appealing to first-time smokers, including youths. It also prohibits tobacco companies from using terms such as "low tar," "light" or "mild," requires larger warning labels on packages, and restricts advertising of tobacco products.

********************************

To learn more about Coleman Research Group please visit the Coleman Research Group website or at any of the links below:


About Coleman Research Group
Coleman Research Group Testimonials
Coleman Research Group on LinkedIn
Coleman Research Group on Facebook
Coleman Research Group on Flickr
Coleman Research Group on Squidoo
Coleman Research Group on Namyz
Coleman Research Group on Twitter
Coleman Research Group on Review-Inc
Coleman Research Group Contact Us
Coleman Research Group on 800 Review
Coleman Research Group on Blogspot
Coleman Research Group on Jobster
Coleman Research Group's Knowledge Broker

No comments: